Skip to content

DOvEEgene/WISE Genomics: Diagnosing Ovarian and Endometrial Cancer Early Using Genomics

Ovarian Neoplasms | Endometrial Neoplasms | Ovarian Cancer | Endometrial Cancer | Early Diagnosis | Safety |...

This study aims to develop and validate a test for detecting ovarian and endometrial cancers early. It relies on detecting somatic mutations that are associated with these cancers from a uterine pap test. A saliva sample is also collected that acts as an internal control and has the ability to detect deleterious germline mutations associated with common hereditary cancers (such as breast, ovarian, endometrial, colon, and pancreatic cancers). A machine learning classifier is then used to discriminate between cancer and benign disease.

null

Conditions de participation

  • Sexe:

    FEMALE

  • Âges admissibles:

    18 and up

Critères de participation

Case Inclusion:

* Subjects should have suspected or confirmed cancer of the upper genital tract.
* Participant will undergo surgery for tumour removal.

Control inclusion:

• Subjects should be scheduled to have a hysterectomy, bilateral salpingectomy, with or without bilateral oophorectomy, for presumed benign disease.

Lieu de l'étude

Royal Victoria Hospital (Glen Site)
Royal Victoria Hospital (Glen Site)
Montreal, Quebec
Canada

Contactez l'équipe d'étude

Jewish General Hospital
Jewish General Hospital
Montreal, Quebec
Canada

Contactez l'équipe d'étude

Étude parrainée par
McGill University
Participants recherchés
Plus d'informations
ID de l'étude: NCT02288676